Spero Therapeutics (SPRO) Receivables - Net (2023 - 2025)

Spero Therapeutics (SPRO) has reported Receivables - Net for 3 consecutive years, with $25.4 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net fell 48.66% year-over-year to $25.4 million; the trailing twelve-month figure through Dec 2025 stood at $25.4 million (down 48.66% YoY), and the FY2025 full-year result was $25.4 million, down 48.66% from the prior year.
• Receivables - Net grew to $25.4 million in Q4 2025 per SPRO's latest filing, from $868000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $50.8 million in Q2 2024 and bottomed at $868000.0 in Q3 2025.
• Historically, Receivables - Net has averaged $35.9 million across 3 years, with a median of $49.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net climbed 0.49% in 2024, then tumbled 98.28% in 2025.
• Over 3 years, Receivables - Net stood at $49.2 million in 2023, then rose by 0.49% to $49.4 million in 2024, then slumped by 48.66% to $25.4 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $25.4 million, $868000.0, and $24.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.